Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report (Q37877728)

24 August 2017

1 reference

title

Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report (English)

1 reference

24 August 2017

1 reference

9

Andrew D Zelenetz

1 reference

24 August 2017

Thomas E Witzig

1

1 reference

24 August 2017

Paul Fishkin

2

1 reference

24 August 2017

Leo I Gordon

3

1 reference

24 August 2017

Stephanie A Gregory

4

1 reference

24 August 2017

Samuel Jacobs

5

1 reference

24 August 2017

Roger Macklis

6

1 reference

24 August 2017

Peter McLaughlin

7

1 reference

24 August 2017

Oliver Press

8

1 reference

24 August 2017

publication date

23 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

52

1 reference

24 August 2017

issue

7

1 reference

24 August 2017

page(s)

1188-1199

1 reference

24 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

New treatment options have changed the survival of patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

131I-tositumomab therapy as initial treatment for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.570396

10.3109/10428194.2011.570396

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference